|
- Revolutionary Medicines Catalyzed by Protein Degradation | Kymera . . .
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation
- Pipeline - Kymera Therapeutics
Kymera’s pipeline is focused on addressing disease targets where there is significant patient need and where we believe protein degradation is the only or best way to improve the standard of care
- Our Company - Kymera Therapeutics
Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines that address critical health problems and dramatically improve patients’ lives
- Kymera Overview | Kymera Therapeutics, Inc.
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system
- Leadership | Kymera Therapeutics
Kymera’s seasoned leaders bring the insights and experience needed to accelerate progress and change patient lives
- About Us - Kymera Therapeutics
About Us Our Company Leadership Kymera Cares Science Innovation Our Approach Pipeline
- Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b . . .
Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions
- Media - Kymera Therapeutics
Read news and insights on how Kymera is advancing a new class of small molecule medicines using targeted protein degradation
|
|
|